Patients with end-stage renal disease (ESRD) have an increased risk of all-cause mortality. The prognostic value of the new cardiac biomarkers, cardiotrophin 1 (CT-1) and galectin 3 (GAL-3), has not yet been defined in hemodialysis (HD) patients. The aim of this study was to determine the use of these novel biomarkers for predicting mortality in HD patients. Plasma GAL-3 and CT-1 concentrations were determined (at baseline) in 88 HD patients followed for 22.2 ± 4.7 months. During the follow-up period, 21 (23.9%) deaths were recorded. According to Cox analysis, the cutoff point for GAL-3 as a predictor of mortality was 23.73 ng/mL, while the cutoff point for CT-1 as a predictor of mortality was 36 pg/mL. In univariate analysis, only GAL-3 >23.73 ng/mL was an independent predictor of mortality (hazard ratio 2.60; 95% confidence interval, 1.09-6.18). In a multivariable Cox proportional hazards model, GAL-3 levels above the cutoff value remained an independent predictor of all-cause mortality. Our data suggest that similar to the general population, GAL-3 is an independent predictor of mortality in HD patients.
PippiasMStelVSAbad DiezJM. Renal replacement therapy in Europe: a summary of the 2012 ERA-EDTA Registry Annual Report. Clin Kidney J. 2015;8(3):248–261.
2.
JagerKJLindholmBGoldsmithD. Cardiovascular and non-cardiovascular mortality in dialysis patients: where is the link?Kidney Int Suppl. 2011;1(1):21–23.
3.
de JagerDJGrootendorstDCJagerKJ. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA. 2009;302(16):1782–1789.
4.
MichosEDWilsonLMYehHC. Prognostic value of cardiac troponin in patients with chronic kidney disease without suspected acute coronary syndrome: a systematic review and meta-analysis. Ann Intern Med. 2014;161(7):491–501.
5.
VoroneanuLSiriopolDNistorI. Superior predictive value for NTproBNP compared with high sensitivity cTnT in dialysis patients: a pilot prospective observational study. Kidney Blood Press Res. 2014;39(6):636–647.
6.
PaniaguaRVenturaMDAvila-DiazM. NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients. Nephrol Dial Transplant. 2010;25(2):551–557.
7.
RackiSZaputovicLMavricZVujicicBDvornikS. C-reactive protein is a strong predictor of mortality in hemodialysis patients. Ren Fail. 2006;28(5):427–433.
8.
JougasakiM. Cardiotrophin-1 in cardiovascular regulation. Adv Clin Chem. 2010;52:41–76.
9.
Lopez-AndresNMartin-FernandezBRossignolP. A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. Am J Physiol Heart Circ Physiol. 2011;301(6):H2372–H2382.
10.
Gamella-PozueloLFuentes-CalvoIGomez-MarcosMA. Plasma cardiotrophin-1 as a marker of hypertension and diabetes-induced target organ damage and cardiovascular risk. Medicine (Baltimore). 2015;94(30):e1218.
11.
Lopez-AndresNRousseauAAkhtarR. Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction. Hypertension. 2012;60(2):563–573.
12.
HungHCLuFHOuHY. Cardiotrophin-1 is associated with increased risk of arterial stiffness. Biomark Med. 2015;9(2):123–130.
13.
GonzalezALopezBRavassaS. Cardiotrophin-1 in hypertensive heart disease. Endocrine. 2012;42(1):9–17.
14.
SongKWangSHuangBLucianoASrivastavaRManiA. Plasma cardiotrophin-1 levels are associated with hypertensive heart disease: a meta-analysis. J Clin Hypertens (Greenwich). 2014;16(9):686–692.
15.
FilipeMDMeijersWCRogier van der VeldeAde BoerRA. Galectin-3 and heart failure: prognosis, prediction & clinical utility. Clin Chim Acta. 2015;443:48–56.
16.
YuLRuifrokWPMeissnerM. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 2013;6(1):107–117.
17.
TangWHShresthaKShaoZ. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol. 2011;108(3):385–390.
18.
LokDJLokSIBruggink-Andre de la PortePW. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol. 2013;102(2):103–110.
19.
YancyCWJessupMBozkurtB. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–239.
20.
O’SeaghdhaCMHwangSJHoJEVasanRSLevyDFoxCS. Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol. 2013;24(9):1470–1477.
21.
DrechslerCDelgadoGWannerC. Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies. J Am Soc Nephrol. 2015;26(9):2213–2221.
22.
KhanSQKellyDQuinnPDaviesJENgLL. Cardiotrophin-1 predicts death or heart failure following acute myocardial infarction. J Card Fail. 2006;12(8):635–640.
LinYHChouCHWuXM. Aldosterone induced galectin-3 secretion in vitro and in vivo: from cells to humans. PLoS One. 2014;9(9):e95254.
25.
MeijersWCvan der VeldeARPascual-FigalDAde BoerRA. Galectin-3 and post-myocardial infarction cardiac remodeling. Eur J Pharmacol. 2015;763(pt A):115–121.
26.
Madrigal-MatuteJLindholtJSFernandez-GarciaCE. Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis. J Am Heart Assoc. 2014;3:e000785.
27.
PuglieseGIacobiniCPesceCMMeniniS. Galectin-3: an emerging all-out player in metabolic disorders and their complications. Glycobiology. 2015;25(2):136–150.
28.
Nikolic-PatersonDJWangSLanHY. Macrophages promote renal fibrosis through direct and indirect mechanisms. Kidney Int. 2014;4(1):34–38.
